Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Approves Cephalon’s CLL Therapy Treanda With Broad Label

Executive Summary

A broad label for Cephalon's Treanda could increase the sales potential for the chronic lymphocytic leukemia therapy, which can be used across multiple lines of treatment and as monotherapy or in combination regimens

You may also be interested in...

Cephalon’s Treanda Approved For Indolent Non-Hodgkin’s Lymphoma

Firm says convenient dosing schedule is a plus for the drug, though it will be combined – not competing – with other NHL chemotherapy agents.

FTC Sues Cephalon For Anticompetitive Side Deals In Reverse Settlements

The Federal Trade Commission is once again challenging reverse settlements between a brand name company and its would-be generic competitors. This time around, the agency is focusing on side deals tacked onto the settlements, contending they constitute unfair competition

The Year Ahead: Controversial NDAs Could Entangle FDA In ‘08; Where Are The Oncologics?

Looking ahead at FDA's review calendar for 2008, the agency will be wrestling with several enigmatic decisions as it considers applications for fibromyalgia and chronic fatigue syndrome, controversial diseases with nebulous definitions and diagnoses

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts